[Clinical Analysis of Autologous Hematopoietic Stem Cell Transplantation in Treatment of Mantle Cell Lymphoma: a Multicenter Retrospective Study].
[OBJECTIVE] To investigate the efficacy and prognostic factors of autologous hematopoietic stem cell transplantation (ASCT) in the treatment of mantle cell lymphoma (MCL) in the real world.
APA
Pang L, Yang P, Jing HM (2026). [Clinical Analysis of Autologous Hematopoietic Stem Cell Transplantation in Treatment of Mantle Cell Lymphoma: a Multicenter Retrospective Study].. Zhongguo shi yan xue ye xue za zhi, 34(1), 53-59. https://doi.org/10.19746/j.cnki.issn.1009-2137.2026.01.008
MLA
Pang L, et al.. "[Clinical Analysis of Autologous Hematopoietic Stem Cell Transplantation in Treatment of Mantle Cell Lymphoma: a Multicenter Retrospective Study].." Zhongguo shi yan xue ye xue za zhi, vol. 34, no. 1, 2026, pp. 53-59.
PMID
41846337
Abstract
[OBJECTIVE] To investigate the efficacy and prognostic factors of autologous hematopoietic stem cell transplantation (ASCT) in the treatment of mantle cell lymphoma (MCL) in the real world.
[METHODS] The clinical data of 85 MCL patients who underwent ASCT in Peking University Third Hospital and other Chinese centers from January 2005 to December 2021 were retrospectively analyzed. The patients were treated with rituximab-based chemotherapy before transplantation, and the effects of clinical characteristics, treatment regimens and biological indicators on overall survival (OS) and progression-free survival (PFS) were observed.
[RESULTS] Among the 85 patients, there were 65 males and 20 females with a median age of 53 (34-68) years, 11 cases of blastic and pleomorphic type and 74 cases of classical type. According to Ann Arbor staging, 5 cases were in stage I-II and 80 cases were in stage III-IV. There were 18 cases with Ki-67≥50%, 29 cases with B symptoms, and 68 cases with external involvement. High-dose cytarabine was used in 56 patients, and 31 patients were in a relapsed/refractory state. With a median follow-up of 51 (12-202) months after ASCT, the estimated 5-year PFS rate was (68.4±6.0)%, and the estimated 5-year OS rate was (87.4±4.6) %. Multivariate Cox regression analysis showed that MIPI-c intermediate-high/high risk (=4.461, 95% : 1.822-10.918, =0.001) and no maintenance treatment (=3.127, 95% : 1.398-6.991, =0.005) were independent adverse prognostic factors for PFS, and relapsed and refractory state(=4.727, 95% : 1.005-22.234, =0.049) were independent adverse prognostic factors for OS.
[CONCLUSION] ASCT consolidation therapy plays an important role in improving PFS and OS of MCL patients with young age and good general condition, especially for those with MIPI-c low/low-intermediate risk, receiving maintenance therapy with new drugs after ASCT, and non-relapsed/refractory state.
[METHODS] The clinical data of 85 MCL patients who underwent ASCT in Peking University Third Hospital and other Chinese centers from January 2005 to December 2021 were retrospectively analyzed. The patients were treated with rituximab-based chemotherapy before transplantation, and the effects of clinical characteristics, treatment regimens and biological indicators on overall survival (OS) and progression-free survival (PFS) were observed.
[RESULTS] Among the 85 patients, there were 65 males and 20 females with a median age of 53 (34-68) years, 11 cases of blastic and pleomorphic type and 74 cases of classical type. According to Ann Arbor staging, 5 cases were in stage I-II and 80 cases were in stage III-IV. There were 18 cases with Ki-67≥50%, 29 cases with B symptoms, and 68 cases with external involvement. High-dose cytarabine was used in 56 patients, and 31 patients were in a relapsed/refractory state. With a median follow-up of 51 (12-202) months after ASCT, the estimated 5-year PFS rate was (68.4±6.0)%, and the estimated 5-year OS rate was (87.4±4.6) %. Multivariate Cox regression analysis showed that MIPI-c intermediate-high/high risk (=4.461, 95% : 1.822-10.918, =0.001) and no maintenance treatment (=3.127, 95% : 1.398-6.991, =0.005) were independent adverse prognostic factors for PFS, and relapsed and refractory state(=4.727, 95% : 1.005-22.234, =0.049) were independent adverse prognostic factors for OS.
[CONCLUSION] ASCT consolidation therapy plays an important role in improving PFS and OS of MCL patients with young age and good general condition, especially for those with MIPI-c low/low-intermediate risk, receiving maintenance therapy with new drugs after ASCT, and non-relapsed/refractory state.
MeSH Terms
Humans; Lymphoma, Mantle-Cell; Hematopoietic Stem Cell Transplantation; Middle Aged; Retrospective Studies; Female; Male; Aged; Transplantation, Autologous; Adult; Prognosis; Treatment Outcome
같은 제1저자의 인용 많은 논문 (3)
- Development of a lymph node-homing peptide vaccine targeting C-C chemokine receptor 7-positive dendritic cells with enhanced antitumor immunity.
- Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: A retrospective cohort study.
- Immune checkpoint inhibitor-related T-cell-mediated rejection increases the risk of perioperative graft loss after liver transplantation.